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 1 
INTRODUCTION 
 
Diabetes Mellitus is a group of metabolic disorders characterized 
by a deficiency of insulin secretion and / or insulin effect, which causes 
hyperglycemia, disturbances of carbohydrate, fat and protein metabolism 
and a constellation of chronic complications. Diabetes is and will remain 
a threat to global health .World wide diabetes probably affects 150 
million people and its prevalence is predicted to double by 2015. The 
incidence of diabetes is showing an alarming rise in developing countries, 
particularly in India3. 60-80% of the diabetics in developed countries are 
obese. Whereas in India we find that clinical profile of diabetics is 
different1. 
Most of the patients attending our diabetic clinic are not obese as 
defined by existing parameters such as BMI. It is interesting to note that 
most patients fall in normal weight group and some even lean group. 
Obesity in type 2 diabetes is less common in Indian population compared 
to western population1,4. So, it is worth studying the clinical profile of 
lean type 2 diabetes, by comparing with normal and obese population 
with type 2 diabetes. 
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REVIEW OF LITERATURE 
 
 Diabetes Mellitus comprises a group of metabolic disorders that 
share the phenotype of hyperglycemia due to absolute or relative 
deficiency of insulin. Several distinct types of Diabetes Mellitus exist and 
are caused by a complex interaction of genetics, environmental factors 
and life style choices. Lack of insulin affects the metabolism of 
carbohydrates, protein and fat and causes a significant disturbance of 
water and electrolyte homeostasis. Though acute metabolic 
decompensation is fatal, long standing metabolic derangement is 
frequently associated with permanent and preventable functional and 
structural changes in the cells of the body, with those of the vascular 
system being particularly susceptible5,6. These changes lead to the 
development of well defined clinical entities the so called complications 
of diabetes which characteristically affect the eye, kidney and the nervous 
system. 
 
Classification2 
Although all forms of DM are characterised by hyperglycemia the 
pathogenic mechanisms by which hyperglycemia arises differ widely. 
Some forms of DM are characterised by an absolute insulindeficiency or 
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a genetic defect leading to defective insulin secretion, whereas other 
forms share insulin resistance as their underlying etiology. 
 
ETIOLOGIC CLASSIFICATION OF DIABETES MELLITUS32 
I. Type 1 diabetes 
A. Immune mediated 
B. Idiopathic 
 
II. Type 2 diabetes 
III. Other specific types 
A. Genetic defects of b - cell function 
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug - or chemical induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndromes sometimes associated with diabetes 
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Other types of Diabetes Mellitus2 
Other etiologies of Diabetes Mellitus include specific genetic 
defects in insulin secretion or action, metabolic abnormalities that impair 
insulin secretion, and a host of conditions that impair glucose tolerance. 
Maturity onset diabetes of the young (MODY)2 is a subtype of Diabetes 
Mellitus characterised by autosomal dominant inheritance, early onset of 
hyperglycemia and impairment in insulin secretion. Mutations in the 
insulin receptor cause a group of rare disorders characterised by severe 
insulin resistance. Diabetes Mellitus can result from pancreatic exocrine 
disease- pancreatitis, fibrocalculous pancreatopathy, haemochromatosis 
,etc when the majority of pancreatic islets (>80%) are destroyed. 
Endocrinopathies such as Acromegaly and Cushing's disease also, 
present with Diabetes Mellitus.Rarely viral infections such as rubella, 
coxsackie and cytomegalo viruses  have been implicated in pancreatic 
islet cell destruction.Drugs and Chemicals  such as Glucocorticoids, 
immunosuppressives, chemotherapeutic agents, B-blockers, thiazides, 
pentamidine,vacor also play a role in the causation. 
 
Gestational diabetes mellitus 
Insulin resistance related to the metabolic changes of late 
pregnancy increases insulin requirements and may lead to hyperglycemia 
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or impaired glucose tolerance.These women have a substantial risk of 
developing Type 2 diabetes in later life. 
Lean body type 2 diabetes mellitus patients have severe basal 
hyperglycemia with low circulatory levels of insulin while C-peptide 
levels are similar to those of patients with classic type 2 Diabetes 
mellitus. Studies on hepatic glucokinase levels & hepatic microsomal 
enzymes (mixed function oxidase & cytochrome P 450) using antipyrine 
& lidocaine as in vivo probes revealed hyperactivity with increased futile 
cycles of CHO metabolism in lean body type 2 patients. These hepatic 
metabolic features are likely to be responsible for excess insulin 
utilization & extraction during first pass in the liver leading to low 
peripheral circulating levels. Homocysteine levels are also low suggesting 
efficient metabolic status12,13. 
Auto immune destruction11 of beta cells is not the cause of 
hypoinsulinemia as levels of ICA-512 / IA2 (islet cell antibody)and anti-
GAD (anti glutamic acid decarboxylase) antibodies are similar to those in 
patients with classical type 2 diabetes mellitus & much lower than those 
in type1 diabetes mellitus. In this way, it differs from the latent auto 
immune diabetes in aduls (LADA) which present at a later age.  
The metabolic profile reveals normal HDL cholesterol levels9,10 
with typeIV hyperlipoproteinemia in glycemic uncontrolled states. 
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Proteinuria found in uncontrolled metabolic states often reverses 
suggesting endothelial cell dysfunction. 
Lean body type 2 diabetes mellitus is not mere anthropometric 
variant of classical type 2 diabetes mellitus but constitute an independent 
variant of type 2 diabetes mellitus7,8,14 with inherent peculiarities in 
insulin kinetics in the hepatic bed along with altered profile & behaviour 
of key enzymes related to CHO metabolism. These peculiarities are 
reflected in the peripheral circulation as states of hypoinsulinemia, 
hyperglycemia, dyslipidemia12,16 without low HDL C, raised TGL & 
fewer other markers for atherosclerosis which make these diabetics less 
prone to develop macro vascular disease14-17, while peripheral neuropathy 
and consequences of hyperglycemia like infections & proteinuria 
dominate the clinical picture. 
 
Epidemiology 
Diabetes remains a threat to global health. World wide the 
prevalence of Diabetes is estimated to increase from 4% in 1995 to 5.4% 
by the year 202519. India has the dubious distinction of having the largest 
number of diabetics in the world. The prevalence 'of Diabetes in India 
Study (PODIS) showed that type 2 Diabetes Mellitus was found in 7.06% 
of the population, which is expected to double by 2015. Diabetes Mellitus 
 7 
is the leading cause of end stage renal disease, non traumatic lower 
extremity amputations and adult blindness in U.S. The increasing 
prevalence of Diabetes Mellitus in developed countries is largely 
attributed to increasing obesity and reduced activity levels. The 
prevalence of Type 2 DM and its harbinger, IGT is highest in certain 
pacific islands, intermediate in countries such as India1 and United States, 
relatively less in Russia and China. This variability is likely due to 
genetic, behavioral and environmental factors. The pattern and profile are 
very different in India compared to the west1.  
 
Criteria for the Diagnosis of Diabetes Mellitus20 
o Symptoms of Diabetes plus random blood glucose 
concentration > 11.1 mmol/L (200 mg/dl)(a)  (or) 
o Fasting plasma glucose > 7.0 mmol/L (126 mg/dl)(b) (or) 
o Two hour plasma glucose > 11.1 mmol/L (200 mg/dl) during an 
oral glucose tolerance test.(c) 
o HbA1C>/=6.5%(d) 
a) Random is defined as without regard to time since the last 
meal. 
b) Fasting is defined as no caloric intake for at least 8 hours. 
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c) The test should be performed using a glucose load containing 
the equivalent of 75 gm anhydrous – glucose dissolved in 
water: not recommended for routine clinical use. 
d)  The test should be performed in a laboratory that is NGSP 
certified and standardized to the DCCT assay. 
Source: Adapted from American Diabetes Association, 2010. 
 
Table 2 
Diagnostic Criteria for Pre-Diabetes and Diabetes20 
Test IFG IGT Diabetes Gestational Diabetes* 
FPG 100-125 Not defined  ³ 126 mg/dl ³ 95 mg/dl 
RPG Not defined Not defined ³ 200 mg/dl Not defined 
75-g OGTT 2-
hour plasma 
glucose 
Not defined 140-199 mg/dl ³ 200 mg/dl Not defined 
100-g OGTT Not defined Not defined Not defined 
1-hour: ³ 180 
mg/dl 
2-hour: ³ 155 
mg/dl 
3-hour: ³ 140 
mg/dl 
AIC Not defined** 
Not 
defined** ³ 6.5% Not defined 
 
Adapted from ADA – 2010 
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PATHOGENESIS5,6 
Type 1 Diabetes Mellitus 
Type 1 Diabetes Mellitus develops as a result of the synergistic 
effects of genetic, environmental and immunologic factors5,6 that 
ultimately destroy the pancreatic beta cells. 
1. Genetic Factors 
Account for one third of the susceptibility to Type 1 Diabetes, the 
inheritance of which is polygenic. Over 20 different regions of the human 
genome show some linkage with type 1 diabetes, but most interest has 
focused on the human leucocyte antigen (HLA), on the short arm of 
chromosome 6. The HLA haplotypes DR3 and / or DR4 alleles are 
associated with increased  susceptibility to type 1 diabetes. 
2. Environmental factors 
Although genetic susceptibility be a prerequisite for the 
development of type 1 diabetes, the concordance rate between 
monozygotic twins is less than 40%. Environmental factors have an 
important role in promoting clinical expression of the disease. 
The hygiene hypothesis 
 Lack of exposure to pathogenic organisms in early childhood 
limits maturation of the immune system and increases susceptibility to 
autoimmune disease. 
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3. Viruses 
Several viruses have been implicated, including mumps5,6, 
Coxsackie B4, retroviruses, rubella (in utero) Cytomegalovirus and 
Epstein–Barr virus. 
 
4. Diet 
Bovine serum albumin (BSA), a major constituent of cow's milk, 
has been implicated in triggering type 1 diabetes. It has been shown that 
children who are given cow's milk early in infancy are more likely to 
develop type 1diabetes than who are breast fed. 
 
5. Stress 
Stress may accelerate the development of type 1diabetes, by 
increasing counter regulatory hormones and possibly by modulating 
immune activity. 
 
6. Immunological factors 
Type 2 diabetes is a slow T cell mediated autoimmune disease. 
Many studies have produced evidence that destruction of the insulin 
secreting cells in the pancreatic islets takes place over many years. 
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Pathogenesis of Type 1 Diabetes 
 
Normal islet cells 
 
? Viral infection in pancreatic beta cells 
 
Secretion of interferon α – by pancreatic beta cells 
 
Hyper expression of class 1 MHC Antigen within islets 
 
Insulitis 
 
Selective destruction of beta cells  
(glucagon secretion preserved) 
 
Insulin deficient islet 
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Type 2 Diabetes Mellitus 
Type 2 Diabetes mellitus commonly occurs in subjects who are 
obese and insulin resistant, but these two factors alone are insufficient to 
cause diabetes unless accompanied by impaired beta cell function. 
 
1. Genetics 
Genetic factors are more important in the etiology of type 2 DM 
than type 1 diabetes, as shown by studies in monozygotic twins where 
concordance rates of type 2 diabetes approaches 100%. 
 
2. Environmental Factors 
The majority of cases of type 2 diabetes are multifactorial in 
nature, with interaction of environmental and genetic factors. 
 
a) Life style: Overeating, fastfood eating habits especially when 
combined with obesity and underactivity. 
b) Malnutrition in utero:  It is proposed that, (but not yet proven), 
malnutrition in utero may programme beta cell development and 
metabolic functions at a critical period, so predisposing to type 2 diabetes 
later in life. 
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c) Age: Age is an important risk factor for type 2 diabetes. Type 2 
Diabetes is principally a disease of the middle aged and elderly, affecting 
10% of the population over the age of 65. 
 
d) Pregnancy: During normal pregnancy, insulin sensitivity isreduced 
through the action of placental hormones and this affects glucose 
tolerance. 
 
Pathogenesis of Type 2 Diabetes Mellitus5,6 
i) Insulin resistance 
ii) Pancreatic Beta cell failure 
1. Insulin Resistance 
Increased hepatic production of glucose and resistance to the action 
of insulin in muscle are invariable in both obese and non obese patients 
with type 2 diabetes. Insulin resistance may be due to 
a) an abnormal insulin molecule 
b) an excessive amount of circulating antagonists or 
c) Target tissue defects  
The last is the most common cause of insulin resistance in type 2 
diabetes. 
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2. Pancreatic Beta Cell Failure5,6 
In type 2 DM, there is only moderate reduction in the total mass of 
pancreatic islet tissue which is consistent with a measurable fall inplasma 
insulin concentration. Some pathological changes are typical of type 2 
diabetes, most conspicuous of which is deposition of amyloid. While beta 
cell numbers are reduced by 20-30% in type 2 diabetes, alpha cell mass is 
unchanged and glucagon secretion is increased, which may contribute to 
the hyperglycemia5,6. 
 
Some people with type 2 diabetes, most of whom are not 
overweight, have advanced pancreatic beta cell failure at the time of 
presentation and require early treatment with insulin. 
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PATHOGENIC PROCESS OF DIABETES MELLITUS 
Hyperglycemia 
Pre-diabetes Diabetes mellitus 
Type of 
diabetes 
Normal 
glucose 
tolerance 
Impaired 
fasting 
glucose or 
Impaired 
glucose 
tolerance 
Not 
insulin 
requiring 
Insulin 
required 
for 
control 
Insulin 
required 
for 
survival 
Type 1      
Type 2      
Others      
GDM      
Time  
(years) 
     
FPG 100mg/dl 100-125% 126 mg/dl  
2-h PPG 140 mg/dl 140-199mg% 200 mg%  
 
SPECTRUM OF GLUCOSE HOMEOSTASIS AND DIABETES 
MELLITUS 
In most types of DM, the individual traverses from normal glucose 
tolerance to impaired glucose tolerance to overt Diabetes. In some types, 
the changes in glucose tolerance may be bidirectional.  
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COMPLICATIONS OF DM 
Acute Complications 
Diabetic ketoacidosis (DKA) and Hyperglycemic hyperosmolar 
state (HHS) are acute complications2 of diabetes. DKA is seen primarily 
in individuals with type 1 Diabetes Mellitus, and HHS is seen in 
individuals with type 2 Diabetes Mellitus. Both disorders are associated 
with absolute or relative insulin deficiency, volume depletion and altered 
mental status. Both are potentially serious if not promptly diagnosed and 
treated. Side effects of intensive treatment include severe hypoglycemia 
and Lactic acidosis21. 
 
Chronic complications 
Chronic complications2 of DM affect many organ systems and are 
responsible for majority of morbidity and mortality. 
Chronic complications of Diabetes Mellitus2 
Microvascular Macrovascular Others 
Eye disease: 
Retinopathy 
Coronary artery 
disease 
Gastrointestinal 
Macular oedema Peripheral vascular 
disease 
Genito urinary 
 Cerebrovascular 
disease 
Dermatological 
Neuropathy  Cataract 
Sensory and Motor  Glaucoma 
Autonomic  Peiodontal disease 
Nephropathy   
 17 
The risk of complications of both type 1 and type 2 increases as a 
function of the duration of hyperglycemia. They usually become apparent 
in the second decade of hyperglycemia. 
 
Mechanism of complications5,6 
Three major theories have been proposed to explain the emergence 
of complications. 
1. Increased intracellular glucose leads to the formation of advanced 
glycosylation end products (AGEs) via non enzymatic 
glycosylation of cellular proteins. AGEs have been shown to cross 
link proteins, accelerate atherosclerosis, promote glomerular 
dysfunction, reduce nitric oxide synthesis, induce endothelial 
dysfunction and alter the extracellular matrix composition and 
structure.  
2. Hyperglycemia increases glucose metabolism via the sorbitol 
pathway. Increased intracellular glucose is converted to sorbitol by 
the enzyme aldose reductase. Increased sorbitol concentrations 
affect several aspects of cellular physiology and may lead to 
cellular dysfunction. 
3. Hyperglycemia increases the formation of diacylglycerol leading to 
activation of certain isoforms of protein kinase C, which in turn, 
affect a variety of cellular events that lead to Diabetes Mellitus 
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related complications. Finally oxidative stress and free radical 
generation may also promote the development of complications. 
Diabetic Retinopathy 
Diabetic retinopathy is the most common cause of blindness in 
adults. Hyperglycemia increases retinal blood flow and metabolism and 
has direct effects on retinal endothelial cells and pericytes, loss of which 
impairs vascular auto regulation. The resulting uncontrolled blood flow 
increases production of vasoactive substances and endothelial cell 
proliferation resulting in capillary closure. This causes chronic retinal 
hypoxia and stimulates production of growth factors, including vascular 
endothelial growth factor (VEGF) to stimulate endothelial cell growth 
(causing new vessel formation) and increased vascular permeability 
(causing exudative damage). 
Diabetic Nephropathy 
Diabetic Nephropathy is the leading cause of end stage renal 
disease (ESRD) in many countries. 
Mechanism of chronic hyperglycemia to ESRD involves 
1. interaction of soluble factors (AT II, AGEs, Endothelin) 
2. hemodynamic alterations in renal microcirculation. 
3. structural changes in the glomerulus. 
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Diabetic neuropathy 
"A descriptive term meaning a demonstrable disorder, either 
clinically evident or subclinical that occurs in the setting of diabetes 
mellitus without other causes for peripheral neuropathy. The neuropathic 
disorder includes manifestations in the somatic and/or autonomic parts of 
the peripheral nervous system. 
 
Aetiopathogenesis of Diabetic Neuropathy 
Hypotheses concerning the multiple etiologies of diabetic 
neuropathy include a metabolic insult to nerve fibers22, neurovascular 
insufficiency, autoimmune damage, and neurohormonal growth factor 
deficiency. Several different factors have been implicated in this 
pathogenic process. Hyperglycemic activation of the polyol pathway 
leading to accumulation of sorbitol and potential changes in the NAD: 
NADH ratio may cause direct neuronal damage and/ordecreased nerve 
blood flow (Greene et al, 1983). Activation of protein kinase C induces 
vasoconstriction and reduces neuronal blood flow (Veves et al, 2001). 
Increased oxidative stress, with increased free radical production causes 
vascular endothelial damage and reduces nitric oxide bioavailability 
(Cameron et al, 1997). Alternatively, excess nitric oxide production may 
result in formation of peroxynitrite and damage the endothelium and 
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neurons. In a subpopulation of individuals with neuropathy, immune 
mechanisms may also be involved. Reduction in neurotrophic growth 
factors, deficiency of essential fatty acids, and formation of advanced 
glycosylation end products (localized in endoneurial blood vessels 
(Brownlee, 1992) also result in reduced endoneurial blood flow and nerve 
hypoxia with altered nerve function. The result of this multifactorial 
process may be activation of polyADP ribosylation and depletion of ATP, 
resulting in cell necrosis and activation of genes involved in neuronal 
damage. 
 
Diabetic autonomic neuropathy 
A subtype of the peripheral polyneuropathies that accompany 
diabetes, Diabetic autonomic neuropathy (DAN) can involve the entire 
autonomic nervous system (ANS) the vasomotor, visceromotor, and 
ensory fibers of which innervate every organ. Diabetic autonomic 
neuropathy may be either clinically evident or subclinical. It is 
manifested by dysfunction of one or more organ systems 
(e.g.,cardiovascular, gastrointestinal, genitourinary, or ocular). 
Indeed,because the vagus nerve (the longest of the ANS nerves)accounts 
for roughly 75% of all parasympathetic activity and, Diabetic autonomic 
neuropathy manifests first in longer nerves, symptoms suggestive of 
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autonomic dysfunction may be common. They may frequently be due to 
other causes rather than to true autonomic neuropathy. Subclinical 
autonomic dysfunction can however, occur within a year of diagnosis in 
type 2 diabetes patients (Pfeifer et al, 1984). Cardiovascular autonomic 
neuropathy (CAN) is the most clinically important and well-studied form 
of Diabetic autonomic neuropathy as it is associated with various adverse 
outcomes. 
 
Macrovascular Complications2 
1. Cardiovascular Morbidity and Mortality 
Framingham Heart study revealed a marked increase in congestive 
heart failure, coronary artery disease, myocardial infarction (MI), 
Peripheral arterial disease and sudden death (risk increases from one to 
five fold) in DM. American Heart Association recently designated 
Diabetes mellitus as a major risk factor for cardiovascular disease (same 
category as smoking, hypertension and hyperlipedemia). 
The absence of chest pain (silent myocardial ischemia) is common in 
individuals with diabetes and a thorough cardiac evaluation is indicated. 
Coronary artery disease is more likely to involve multiple vessels in 
individuals with diabetes mellitus23. 
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2. Hypertension 
Hypertension in diabetes mellitus can accelerate other 
complications of DM, particularly cardiovascular disease23, and 
nephropathy. Blood pressure goal in individual with diabetes is < 130 /80 
mm Hg. It is often difficult to control hypertension with a single agent 
especially in type 2 DM. 
 
3. Dyslipidemia 
Individuals with diabetes may have severe forms of dyslipidemia. 
Because of additive cardiovascular risk of hyperglycemia and 
hyperlipidemia, lipid abnormalities should be aggressively detected and 
treated23,24. Most common pattern of dyslipidemia is hypertriglyceridemia 
and reduced HDL cholesterol levels. 
Target lipid values10,20 in diabetic individual without cardiovascular 
disease should be, 
¯ LDL < 100 mg/dl 
¯ HDL (>40 mg/dl) in men 
¯ HDL (>50 mg/dl) in women 
¯ Triglycerides < 150 ml/dl  
¯ ADA recommends an LDL level of <70 mg/dl in those with 
cardiovascular disease. 
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4) Lower extremity complications2 
Diabetes is the leading cause of non traumatic lower extremity 
amputations. Foot ulcers and infections are also a major source of 
morbidity in individuals with DM.  
 
5) Infections2 
Individuals with DM have a greater frequency and severity of 
infection. The reasons for this include incompletely defined abnormalities 
in cell mediated immunity and phagocytic function associated with 
hyperglycemia, as well as diminished vascularisation. Cardiac and other 
fungal infections, emphysematous infections of the gall bladder and 
urinary tract, pneumonia and skin and soft tissue infections are all more 
common in diabetic population. However gram negative organisms, 
M.tuberculosis and S. Aureus are also more frequent pathogens. 
 
Diabetic skin complications2 
1. Diabetic dermopathy – begins as an erythematous area and evolves 
into an area of circular hyperpigmentation. 
2. Necrobiosis Lipoidica – Diabeticorum – usually begins in the 
pretibial region as an erythematous plaque or papules 
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that gradually enlarge, darken and develop irregular margins with 
atrophic centers and central ulceration. 
3. Acanthosis nigricans – Hyperpigmented velvety plaques seen on the 
neck, axilla, or extensor surfaces, is sometimes a feature of severe insulin 
resistance. 
4. Granuloma Annulare – erythematous plaques on the extremities or 
trunk. 
5. Scleredema – Area of skin thickening on the back or neck at the site of 
previous superficial infections. 
6. Lipoatrophy and Lipohypertrophy 
7. Xerosis and pruritus are common. 
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CLINICAL PROFILE OF LEAN TYPE 2 DIABETES 
Articles review 
1. Clinical profile of lean type 2 diabetes – study conducted at Madras 
Diabetes Research Foundation14, India with 347 lean, 6274 normal 
and 3252 obese type 2 diabetes patients in 2002 observed. 
a.  60% are non obese and lean type 2 DM constituted 3.5%. 
b. Increased prevalence of retinopathy, nephropathy and 
neuropathy in lean type 2 DM patients. 
2. Clinical profile of type 2 diabetes mellitus and body mass index25 – 
is there any correlation?. Study conducted with 500 patients at 
Manipal, Kasthurba Medical College by Prabhu Mukhyaprana in 
2004 observed, 
a. Majority (65%) belonged to normal weight diabetes 
group, and 7.1% were lean diabetics. 
b. Most of the lean diabetics were males (65%) with less 
positive family history. 
c. There was linear increase in number of patients having 
abnormal WHR with increase in BMI. 
d. Microvascular complications were found in similar 
proportion in all groups. 
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e. Lean diabetics are less prone to develop macro vascular 
complications like HT and IHD. 
f. Lean diabetics have more severe hyperglycemia and poor 
metabolic control. 
g. Analysis of lipid profile showed, all the parameters were 
lower in lean diabetics compared to other groups i.e. 
normal and obese patients. 
3. Clinical profile of lean body weight type 2 DM patients in 
comparison with obese and non obese type 2 diabetes patients: 
Study conducted at Jamnagar, M.P. Shah Medical College by 
Gohel DR, Deszi VK26, in 2002-2003 observed very similar results 
as previous studies. In addition, 
i) Increased incidence of higher fasting plasma glucose 
(239+42.5) in lean diabetics. 
ii) Peripheral neuropathy (52%) and infections (42%) were the 
commonest presenting clinical features in lean patients26. 
4. Increased prevalence of Retinopathy, nephropathy and neuropathy 
in lean diabetics; Mohan et al. 
5. Studies by Banerji et al and Dass et al had showed slight increase 
in Triglycerides (TGL) and HDL in lean diabetes. 
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6. Japanese study by Ikeda et al showed no major differences in lipid 
profile in lean diabetics irrespective of glycemic status. 
One observation from the National Institute of Diabetes and 
Digestive kidney diseases, Phoenix, that “NIDDM in the presence of low 
BMI is more strongly familial than that at a higher BMI,” warrants 
further study into the possible genetic mechanisms that modulate the 
above factors in Lean Type 2 DM31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND 
OBJECTIVES 
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AIM OF THE STUDY 
 
1. To Study and compare the clinical profile of Lean Body weight 
Type 2 Diabetes Mellitus patients with obese and Normal weight 
Type 2 DM patients, by age, sex, family history and 
Anthropometry. 
2. To compare the "presenting complications" of the lean with normal 
weight / obese type 2 Diabetes patients. 
3. To compare the Biochemical profile of the lean type 2 Diabetes 
with that of normal and obese type 2 DM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS 
AND METHODS 
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MATERIALS AND METHODS 
Type of the study : Cross sectional  
Period of study : January 2010 – September 2010 
Place of study : Annal Gandhi Memorial Government Hospital,  
  Trichy.  
No.of Patients : 100 
Materials  : Type 2 Diabetes Mellitus patients 
The hundred patients were divided into three groups based on BMI. 
Body Mass Index (BMI) 
Group A: BMI < 18.5 Kg/m2 (Lean Body Weight Type 2DM) 
Group B: BMI, between 18.5 and 24.9 Kg/m2 (Normal Weight Type 2 
DM). 
Group C: BMI > 30Kg/m2 (Obese Type 2 DM) 
A careful detailed history were taken from each person, i.e. Age of 
onset, duration, any positive family history, dietary pattern, presenting 
complaints – at the time of diagnosis etc. Detailed examination was done 
for all the hundred patients to find out various complications, if any. 
Biochemically, Blood glucose (Both fasting and post prandial), Blood 
urea, Serum Creatinine, Lipid profile were analysed in all the three 
groups. 
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Selection of cases 
Cases included in the study were selected as per the records 
available with them. Duration of disease, Body Mass Index, Waist Hip 
Ratio, current Blood Glucose, Urea, Serum Creatinine and Lipid profile 
were taken into consideration. 
 
Exclusion Criteria for cases 
1. Presence of history of pulmonary tuberculosis. 
2. Presence of other chronic illnesses that could affect body 
weight like chronic liver disease and chronic kidney disease. 
3. Type 2 Diabetes patients with Age of onset less than 30 
years. 
4. History wise, particularly in lean patients those who were   
normal or obese at the time of presentation, but lost  body  
weight significantly after the detection of type2 Diabetes 
mellitus. 
5. Patients with history of Cancer /HIV. 
6. Over weight patients with BMI between 25-30. 
 
Selection of Controls 
Control cases were normal weight as well as obese patients with 
Type 2 Diabetes Mellitus. 
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Methods 
1. Height (in meter), Weight (in kg) measured in all patients. 
BMI (Body Mass Index) calculated based on the formula, 
BMI (kg/m2) = Weight (kg)/Height (in m2) (Quetelet) 
2. Waist hip Ratio (W/H Ratio)  
o 'Waist Circumference' measured at midpoint between the 
costal margin and anterior superioriliac spine. Hip 
measurement taken as maximum diameter at the greater 
trochanter.  
o Waist / Hip Ratio (WHR) was calculated in each case.  
o Waist Hip ratio was considered abnormal if > 0.9 for males 
and > 0.8 for females.  
Patients were clinically screened for microvascular and 
macrovascular complications. 
ë Patients were considered as hypertensives if blood pressure was > 
130/80 mm Hg. 
ë Patients were considered as having ischemic heart disease based on 
ischemic changes in the ECG or by demonstrating regional  wall 
motion abnormalities in the echocardiogram for selected  patients. 
ë Ophthalmoscopy was done to diagnose diabetic retinopathy. 
Neuropathy was diagnosed, based on subjective symptoms or 
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objective evidence in the form of loss of ankle jerk or glove and 
stocking type of anaesthesia. 
ë Nephropathy was diagnosed based on blood urea and serum 
creatinine values and Ultrasound abdomen and urine microalbumin 
in selected patients.  
ë Fasting, postprandial glucose, fasting lipid profile and other 
relevant investigations were done in each case. 
 
Definitions and Cut Off values for the study28 
1. Body Mass Index (BMI) 
18.5-24.9 (kg/m2) – taken as normal value 
<18.5 (kg/m2) – lean body weight 
>30 (kg/m2) – obese body weight 
 
2. Waist Hip Ratio 
WHR - >0.85– was taken as abnormal value in females. 
>0.9 in males as abnormal value. 
 
3. Fasting 'Hyperglycemia'  
Fasting Hyperglycemia means if Blood glucose value >126 mg% 
In the fasting state. 
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4. Post prandial Hyperglycemia 
Postprandial blood sugar measured at 2 hours after the meals. Post 
prandial hyperglycemia means if value > 200 mg% 
 
5. Lipid Profile 
Lipid profile taken after 8 hours overnight fasting. 
 
Range of Normal Values 
¯ Free cholesterol < 200 mg/dl 
¯ LDL < 100 mg/dl 
¯ HDL (>40 mg/dl) in men 
¯ HDL (>50 mg/dl) in women 
¯ Triglycerides < 150 ml/dl  
¯ ADA recommends an LDL level of <70 mg/dl in those with 
cardiovascular disease. 
Others 
Blood is drawn from each patient under recommended ideal 
conditions to determine the fasting and postprandial Blood sugar, urea, 
serum creatinine and Lipid profile. 
Ethical Committee Approval 
The present study was approved by the ethical committee.  
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Statistical Analysis 
Statistical Analysis of data was done by using the software – 
Statistical Packages for Social Sciences (SPSS version 13.0) developed 
by LEAD TOOLS CORPORATION. 
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RESULTS AND OBSERVATIONS 
 
TABLE - 1 
CHARACTERISTICS OF THE STUDY POPULATION 
 
S. No CHARACTERISTICS RANGE MEAN S.D. 
1. AGE 35-65 56.1 8.877 
2. BMI 16-35 2.13 0.0719 
3. WAIST HIPRATIO    
 MALES 0.78-1.0   
 FEMALES 0.78-1.0   
 TOTAL  1.64 0.04842 
4. 
FASTING BLOOD SUGAR 
90-360 1.93 0.06397 
5. POSTPRANDIAL BLOOD SUGAR 190-500 2.39 0.06948 
6. TOTAL CHOLESTEROL 150-290 1.49 0.05024 
7. TGL 40-350 1.48 0.05021 
8. HDL 25-90 1.43 0.04976 
9. LDL 60-210 1.76 0.04292 
10. VLDL 10-140 32.46 2.095 
11. 
BP: 
SYSTOLIC 100-170 127.18 2.078 
 DIASTOLIC 60-110 82.68 1.262 
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TABLE – 2 
COMPLICATIONS 
S. 
No. CHARACTERISTICS NO % 
1 SEX  MALES 48 48 
  FEMALES 52 52 
2. FAMILY HISTORY  YES 31 31 
  NO 69 69 
3. COMPLICATIONS   
a. CARDIAC  YES 36 36 
  NO 64 64 
b. RENAL  YES 25 25 
  NO 75 75 
c. NEURO  YES 20 20 
  NO 80 80 
d. RETINO  YES 17 17 
  NO 83 83 
e. INFECTIONS  YES 17 17 
  NO 83 83 
f. HYPERTENSION  YES 43 43 
  NO 57 57 
g. BMI LEAN 19 19 
 NORMAL 49 49 
 OBESE 32 32 
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TABLE – 3 
AGE AND BMI 
LEAN NORMAL OBESE AGE 
GROUP 
No. % No % No % 
< 40 Yrs - - 4 44.4 5 55.6 
41- 
50Yrs 
2 14.3 8 57.1 4 28.6 
51- 
60Yrs 
12 24.5 24 48.9 13 26.5 
> 60Yrs 5 17.8 13 46.4 10 35.7 
TOTAL 19  49  32  
 
There is no statistically significant relationship between age and BMI. 
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SEX AND BMI 
TYPE 
LEAN NORMAL OBSES SEX 
NO % NO % NO % 
MALE 8 16.6 22 45.8 18 37.5 
FEMALE 11 21.2 27 51.9 14 26.9 
TOTAL 19  49  32  
 
There is statistically significant relationship between sex and BMI. 
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FAMILY HISTORY AND BMI 
LEAN NORMAL OBSE FAMILY 
HISTORY NO % NO % NO % 
YES 3 9.6 11 35.4 17 54.8 
NO 16 23.1 38 55.1 15 21.7 
TOTAL 19  49  32  
 
Statistically significant at 0.01 level.  
% of lean cases is low in persons with family history. 
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WAIST HIP RATIO AND BMI 
LEAN NORMAL OBESE 
WHR 
NO % NO % NO % 
NORMAL 11 30.5 22 61.1 3 8.3 
ABNORMAL  8 12.5 27 42.2 29 45.3 
TOTAL 19  49  32  
 
There is statistically significant relationship between WHR and BMI. 
‘p’ value 0.01. 
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FASTING BLOOD SUGAR AND BMI 
LEAN NORMAL OBESE FASTING 
BLOOD 
SUGAR NO % NO % NO % 
NORMAL 4 16.7 9 37.5 11 45.8 
ABNORMAL 15 19.7 40 52.6 21 27.6 
TOTAL 19  49  32  
 
There is statistically significant relationship between Fasting blood sugar 
and BMI. 
‘P’: -0.112  Significant at 0.05 level  
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POST PRANDIAL BLOOD SUGAR AND BMI 
LEAN NORMAL OBESE PP BLOOD 
SUGAR NO % NO % NO % 
NORMAL 1 8.3 6 50.0 5 41.6 
ABNORMAL 18 20.5 43 48.9 27 30.7 
TOTAL 19  49  32  
 
There is no statistically significant relationship between PPBS and BMI. 
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LIPID PROFILE AND BMI 
LEAN NORMAL OBESE TOTAL 
CHOLESTEROL NO % NO % NO % 
NORMAL 16 31.4 25 49.0 10 19.6 
ABNORMAL 3 6.1 24 48.9 22 44.9 
TOTAL 19  49  32  
 
There is statistically significant relationship between total cholesterol and 
BMI. 
‘p’ < 0.001. 
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TGL AND BMI 
LEAN NORMAL OBESE 
TGL 
NO % NO % NO % 
NORMAL 16 32.0 27 54.0 20 40.0 
ABNORMAL 3 6.0 22 44.0 12 24.0 
TOTAL 19  49  32  
 
There is statistically significant relationship between TGL and BMI. 
‘p’ < 0.001 
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HDL AND BMI 
LEAN NORMAL OBESE 
HDL 
NO % NO % NO % 
NORMAL 12 26.1 22 47.8 12 26.1 
ABNORMAL 7 12.9 27 50.0 20 37.0 
TOTAL 19  49  32  
 
There is statistically significant relationship between HDL and BMI.  
‘p’: 0.01 - significant at 0.05 level  
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LDL AND BMI 
LEAN NORMAL OBESE 
LDL 
NO % NO % NO % 
NORMAL 12 50.0 8 33.3 4 16.7 
ABNORMAL 7 9.2 41 53.9 28 36.8 
TOTAL 19  49  32  
 
There is statistically significant relationship between LDL andBMI. 
‘p’ < 0.001 
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COMPLICATIONS AND BMI 
COMPLICATIONS 
CARDIAC RENAL HYPERTENSION 
YES NO YES NO YES NO 
BMI 
NO % NO % NO % NO % NO % NO % 
L 3 8.3 16 25.0 6 24.0 13 17.3 2 4.6 17 29.8 
N 18 50.0 31 48.4 11 44.0 38 50.7 19 44.2 30 52.6 
O 15 41.7 17 26.6 8 32.0 24 32.0 22 51.2 10 17.5 
p <0.013 Significant not significant  <0.001 significant 
 
 
BMI AND CARIDO VASCULAR COMPLICATION  
 
 
 
3
18
15
16
31
17
0
5
10
15
20
25
30
35
Lean Normal Obese
BMI
Ca
rd
ia
c
Present Absent
 
BMI AND RENAL COMPLICATION  
 
 
 
6
11
8
13
38
24
0
5
10
15
20
25
30
35
40
Lean Normal Obese
BMI
R
en
al
Present Absent
 
BMI AND HYPERTENSION 
 
 
 
2
19
22
17
30
10
0 5 10 15 20 25 30 35
Lean
Normal
Obese
B
M
I
Hypertension
Present Absent
 48 
 
 
COMPLICATIONS AND BMI 
COMPLICATIONS 
NEUROPATHY RETINOPATHY NFECTIONS 
YES NO YES NO YES NO 
BMI 
NO % NO % NO % NO % NO % NO % 
L 10 45.5 9 11.3 6 35.2 13 15.6 9 52.9 10 13.7 
N 6 27.2 43 53.8 7 41.1 42 50.6 5 29.4 44 60.2 
O 4 18.1 28 35.0 4 23.5 28 33.7 3 17.6 29 39.7 
p < 0.010 significant not significant < 0.001 significant 
BMI AND NEUROPATHY 
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DISCUSSION AND ANALYSIS OF RESULTS 
 
"Diabetes Mellitus" is an age old affliction of man and is the most 
common metabolic disorder all over the world. The incidence of Diabetes 
is showing alarming rise in developing countries, particularly. In India. 
India3 is known as the Diabetic capital of the world. Most of the diabetics 
in developed countries are obese. 
However in India we have a significant number of diabetics who 
are either normal weight or even under weight4. Even though obesity is 
considered as part of Syndrome X in the pathogenesis of type 2 diabetes, 
in our study, out of 100 patients only32 patients were obese. Our study 
included hundred patients. Among 100 patients, 48 are males and 52 are 
females. In our study majority of patients, that is 49 patients (49%) 
belong to normal weight, 32 patients (32%) belong to obese and 19 
patients (19%) belong to lean body weight. 
 
1. Age 
In our study, we found there is no particular age group for lean 
diabetics. But 24.5% of lean diabetics belong to 51-60 years of age, 
57.1% of normal weight patients between 41-50years,and  55.6 %of 
obese patients belong to <40 years age group. 
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2. Sex 
There is statistically significant relationship exist in our study 
between sex and BMI. Slightly higher incidence of female in lean body 
weight (21.2%) and in normal body weight (51.9%) was observed. In 
obese there is male preponderance (37.5%) 
 
3. Family History 
Family history of diabetes is present only in 9.6% of lean diabetics, 
in comparison to 35.4% in normal and 54.8% in obese diabetics. So there 
is lesser incidence of family history among the lean diabetics. 
 
4. Waist Hip Ratio and BMI 
There is a linear increase in number of patients having abnormal. 
Waist Hip ratio with increase in BMI. Among 100 patients studied, 64 
patients have abnormal Waist Hip ratio. Among that it is 12.5% in lean, 
42.2% in normal and 45.3% in obese type 2 diabetics. Eventhough 19% 
(19) of diabetics patients are lean based on BMI, 8 among them have 
abnormal Waist hip ratio. So, Waist hip ratio is a better indicator than 
BMI for assessment of obesity. 
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5. Complication 
Microvascular complications 
Among the microvascular complications neuropathy (45.5%), 
Retinopathy (35.2%) are common in lean diabetics in our study which 
are statistically significant. Only 24% of lean diabetics had nephropathy, 
which is not statistically significant. In normal weight group, incidence of 
neuropathy, retinopathy and nephropathy are 27.2%, 41.1% and 44% 
respectively. In obese patients, incidence of neuropathy, retinopathy and 
nephropathy are 18.1%, 23.5% and 32%respectively. 
 
Macrovascular Complications 
Lean diabetics are less prone to develop macrovascular 
complications – like hypertension and Ischemic Heart Disease. Incidence 
of hypertension is 4.6% in lean patients as compared to 44.2% in normal 
and 51.2%% in obese diabetics. Like wise cardiac complications are low 
in lean diabetics (8.3%)as compared to 50% in normal and 41.7%in obese 
diabetics. 
 
Infections 
In our study, 52.9% of lean patients with type 2 diabetes presented 
with infections as compared to 29.4% in normal and 17.6 % in obese 
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patients. Values are statistically significant- p value < 0.001.Majority of 
the lean diabetics in our study group presented with infections. 
 
Glycemic Control 
Lean diabetics have more severe hyperglycemia with poor 
metabolic control. Lean persons have higher fasting blood sugar levels 
than obese and normal weight type 2 diabetes patients. Similarly post 
prandial  values were also high in lean type 2 DM patients. This has been 
explained by probable low beta cell reserve among lean diabetics. So, 
Lean diabetics are insulinopenic and highly insulin sensitive. 
 
Lipid Profile 
Regarding lipid profile of lean type 2 diabetes patients, all the 
parameters were lower in lean diabetics compared to all other groups. 
Moreover, lean diabetics have slightly higher HDL value as compared to 
normal and obese diabetics, which is statistically significant. Also free 
cholesterol value in lean diabetics are not as high as compared to obese 
patients. So, lean diabetics have favorable lipid profile as compared to 
normal and obese diabetics.  
In contrast to the previous studies, in our study the triglyceride 
levels were not significantly high in lean diabetics. 
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Our study has limitations, as it was hospital based in the tertiary 
care setting. Incidence of complications might be higher compared to 
general population or primary care setting. We did not do HbA1C, insulin 
level assay, C peptide levels and GAD antibodies in our lean diabetics 
due to financial constraints. In conclusion, type 2 diabetic patients need 
not always be obese. Majority (49%) belong to normal weight and 
significant number (19%) of patients are even lean in our study. Thus, 
lean body type 2 DM patients appear to be a distinct variety and a great 
deal of emphasis is to be given on its clinical/biochemical profile and 
natural history. 
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COMPARATIVE ANALYSIS 
 
Our study includes 100 patients with type 2 diabetes. Among them 
normal weight (49%), obese patients (32%) and lean type 2diabetics 
(19%) were identified.  
But the study  
i) Conducted at Manipal by Prabhu Mukhyaprana and Sudha 
Vidyasagar included 500 type 2 diabetic patients between 
July 2000 and January 2001. 
ii) The study conducted by Gohel Dr. Desai VK at M.P. Shah 
Medical College, Jamnagar, published in JAPI, Dec 2003 
included 75 patients with Type 2 Diabetes Mellitus. 
1. Percentage of Lean Body Weight Type 2 DM Population 
In our study, Lean Type 2 DM was observed in 19%, as compared 
to 49% of normal and 32% of obese patients. Study conducted (by 
Mukhyaprana et al) lean were 7.4% and majority (65%) were of normal 
weight. Incidence of lean body weight – Diabetes in various Indian 
studies ranges from 1.6% as in Ramachandran et al. study to as high as 
28% as in Tripathi et al. 
Mohan et al reported an incidence of 3.5%. 
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2. Age Group 
In our study there is no statistically significant relationship between 
age and BMI observed. 
i) But study conducted by Prabhu et al, mean age of onset of 
diabetes in lean were 60.34 + 13.5 years. 
ii) In Gohel DR. et al study it was between 30-40 years. 
 
3. Sex 
In our study, lean type 2 Diabetes patients were slightly higher in 
female sex (21.2%) which was statistically significant.  
i) Study conducted by Prabhu Mukhyaprana M et al observed 
most lean type 2 DM were males (65% of total lean) type 2 
DM which was statistically not significant. 
 
4. Family History 
Positive family history was present only in 9.6% of patients with 
lean body weight type 2 DM as compared to 35.4% in normal weightand 
54.8% in obese patients with type 2 DM which were 
statisticallysignificant. 
i) Study conducted by Prabhu Mukhyaprana et al observed 
positive family history in 45% of lean and 62.6% in normal 
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body weight diabetics, results were similar to studies by – 
Banerji et al and Kannan et al studies. 
ii) Study conducted by Gohel DR et al observed low incidence 
of positive family history (20%) in lean as compared to 40% 
in normal and 44% in obese patients. 
 
5. BMI and WHR – Are they related? 
In our study 12.5% of lean diabetes had abnormal Waist Hip Ratio 
as compared to 42.2%% in normal and 45.3% in obese patients. Waist 
Hip Ratio had a statistically significant ('p' – 0.001). Relationship with 
BMI. Previous study conducted at Manipal observed 48% of lean 
diabetics had abnormal Waist Hip Ratio, stating that significant number 
of lean diabetics (48%) had abnormal Waist Hip Ratio. The Waist Hip 
Ratio may thus be a more sensitive indicator of obesity in Indians25,27. 
 
7. Glycemic Status 
In our study, significant proportion of lean persons had higher 
fasting blood sugar levels than obese patients with Type 2 Diabetes, 
which was statistically significant (p = -0.112) as compared to normal and 
obese patients with Type 2 Diabetes. 
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i) Results were similar to studies done by Kannan et al and 
Italian Study by Pointoroly et al. This has been explained 
based on low – beta cell reserve in these patients. 
ii) Similar results were also observed in study conducted by 
Prabhu Mukyaprana et al. Fasting blood sugar was 
177.08+105.1. 
iii) Postprandial blood sugar values in Lean type 2 DM patients 
were higher, even though statistically not significant. 
 
8. Lipid Profile 
Analysis of lipid profile in our study showed interesting results. 
Type 2 lean diabetics, had lower incidence of dyslipidemia as compared 
to all other groups, even though only HDL relationship with BMI was 
statistically significant. In our study HDL values were slightly higher in 
lean Diabetics, as compared to normal and obese patients which was 
statistically significant (p 0.012). Also free cholesterol value in lean 
diabetics were high as compared to normal weight and obese patients. 
Triglyceride values in lean diabetics were not very high as compared to 
normal and obese diabetics. Previous studies by Banerji et al and Das et 
al had showed slight increase in TGL and HDL in lean diabetics. 
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Japanese study by Ikeda et al showed no major differences in lipid profile 
in lean diabetics, irrespective of glycemic status. 
 
9. Complications 
In our study, increased incidence of microvascular complications 
like neuropathy, retinopathy were observed in lean diabetics which is 
statistically significant. 47.3% of lean patients had neuropathy as a 
presenting feature as compared to 31.5% in normal and 21.1% in obese 
patients with a 'p' value of 0.010 (significant). Retinopathy also increased 
in lean type 2 Diabetics with 35.2% in lean, 41.1%in normal and 23.5% 
in obese patients though it is not statistically significant. In our study 
nephropathy was observed only in 24% of lean patients as compared to 
44%in normal and 32% of obese type 2 diabetics, which is not 
statistically significant. Study conducted at Manipal showed 
microvascular complications were similar in all the 3 groups. 
Macrovascular complications like HT, IHD were less in lean17 diabetics 
as compared to other groups. In our study, the incidence of hypertension 
was 4.6% in lean as compared to 44.2% in Normal and 51.2 % in Obese. 
Incidence of IHD was low in  the lean as compared to  normal and Obese. 
Incidence of hypertension was 8.9% and IHD 10.2% in Nigam et al 
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study. In Manipal study the incidence of IHD was only 2.7% among lean 
and HT in 16.7% of lean diabetics. 
 
Infections 
In our study 52.9% of lean patients with type 2 diabetes presented 
with infections as compared to 29.4% in normal and 17.6%in obese 
patients. Values were specifically significant also. (‘p’ value = < 0.001). 
Mohan et al14 reported increased prevalence of retinopathy, neuropathy 
and nephropathy in lean diabetics. Peripheral neuropathy was the 
commonest presenting complication among lean diabetics in a study by 
Das et al. Peripheral neuropathy and infections were the commonest 
presenting clinical features in lean diabetics observed in study conducted 
by Gohel et al. 
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SUMMARY 
 
ª Total Number of patients studied – 100. Out of 100 patients, 48 
were males and remaining 52 were females. 
ª Number of lean type 2 DM Patients were 19. Among them  44% 
were Males and 56% were Females. 
ª Number of normal weight type 2 diabetics were 49. Among them 
45% were males and 55% were females. 
ª Number of obese type 2 diabetics patients were 32. Among them 
56% were males and 44% were females. 
ª Most of diabetics in our population (52%) had normal body 
weight. Lean type 2 Diabetics form  a significant number (19%). 
ª Low incidence of positive family history in lean type 2 diabetics 
(9.6%) was observed. 
ª Peripheral neuropathy (47.3%), Retinopathy (35.2%) and 
infections (52.9%%) were the major presenting clinical 
complications in lean diabetics. 
ª Most risk factors of atherosclerosis and CAD are less prevalent in 
lean type 2 diabetes (Normal HDL, and total cholesterol on lower 
side). 
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CONCLUSION 
 
a. Majority of type 2 diabetes patients in our population are having 
normal weight (49%) and lean body weight  contributes to 19% 
b. Lean diabetics have more severe hyperglycemia and poor 
metabolic control. They are more prone for microvascular 
complications like neuropathy and retinopathy. 
c. Early treatment with insulin in lean type 2 diabetics is mandatory 
to achieve good glycemic control and to prevent future 
complications. 
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PROFORMA 
PROFORMA 
 
CLINICAL PROFILE OF LEAN BODY WEIGHT TYPE 2 DM 
PATIENTS IN COMPARISON WITH OBESE AND NON-OBESE 
TYPE 2 DM PATIENTS 
Date of Registration    No. 
Name /Age /Sex 
Address 
Occupation 
Sedentary 
Active 
 
New case/ Already treated case How long 
PRESENTING SYMPTOMS AT THE TIME OF DETECTION 
Symptoms   YES   NO 
Polyuria 
Polydypsia 
Polyphagia 
Tiredness 
Weight loss 
Blurring of vision 
Itching 
Vomiting 
Abdominal pain 
Constipation 
Nocturnal Diarrhoea 
Numbness 
Pruritus vulvae 
Sexual Dysfunction 
Balanitis 
joint / body pain 
Ulcer 
 
Previous treatment: Insulin /tablets  
Diet 
Alternative 
 
Previous illness:  M.I 
HT/ Operations 
Jaundice/PT 
 
Family History of Diabetes: Yes/no 
Personal History 
Smoking    Yes/no 
Alcohol    Yes/no 
Vegetarian    Yes/no 
Non- veg    Yes/no 
 
Examination 
General: Acanthosis Nigricans 
Xanthoma / Xanthelasma 
Thyroid swelling 
 
BP:  Lying/Standing 
Pulse 
 
Anthropometry 
Height (cm)/weight(kg) 
Under Wt. (Lean)/Ideal wt/ Obese 
 
BMI 
Waist / hip ratio (WHR) 
 
System 
CVS 
Respiratory 
Abdomen 
CNS 
 
Opthalmological 
Investigations 
Urine - Albumin 
Sugar 
Deposits 
Blood sugar Fasting 
Post prandial 
Blood urea 
Sr. creatinine 
Lipid profile  
TCL 
LDL 
HDL 
VLDL 
TGL 
ECG 
ASSESMENT 
1. Type 2 DM 
lean 
Normal wt 
Obese 
2. Family history: Present/ Absent 
3. Metabolic: Fasting Hyperglycemia Yes/No 
4. vascular: 
IHD    Yes/no 
PVD    Yes/no 
Retinopathy  Yes/no 
Nephropathy  Yes/no 
Neuropathy   Yes/no 
Infections   Yes/no 
Others (specify) Yes/No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
MASTER CHART 
 
S.      
NO NAME TYPE AGE SEX BMI  WHR  
FAMILY 
HISTORY FBS PPBS TC TGL HDL LDL VLDL CVD NEPHRO NEURO RETINO INFECTION HT SBP DBP 
1. Selvamani N 60 1 24.12 2 0.78 1 2 248 480 248 193 45 165 38 2 2 2 2 2 1 150 100 
2. Gnanamal N 54 2 20.5 2 0.9 2 2 191 335 225 209 67 117 41 1 2 2 2 2 2 110 80 
3. Meenambal N 50 2 23.6 2 0.8 2 2 131 206 203 242 86 69 48 2 2 1 2 2 1 150 100 
4. Karuppan L 55 1 15..4 1 0.84 1 2 114 278 167 218 78 70 42 2 1 2 2 1 2 120 80 
5. Annavi O 36 1 30.4 3 0.97 2 1 145 347 256 140 44 187 25 1 1 2 2 2 2 110 80 
6. Jameela L 52 2 18.04 1 0.91 2 2 239 476 190 96 62 109 19 2 1 1 2 1 1 100 70 
7. Murugan L 55 1 16.89 1 0.87 1 2 207 389 166 170 68 73 25 2 2 1 2 1 2 126 80 
8. Danushkodi O 55 1 30.43 3 0.9 1 1 107 214 204 160 36 136 32 2 2 2 2 2 1 160 100 
9. Mumtaz O 45 1 30.36 3 0.97 2 1 336 460 190 153 38 122 30 2 2 2 1 2 1 160 90 
10. Mary L 60 2 17.85 1 0.91 2 2 103 209 166 86 62 87 17 2 1 2 2 1 2 120 78 
11. Samikkanu N 50 1 19.11 2 0.87 1 2 300 428 210 137 41 143 27 2 2 1 2 2 2 120 84 
12. Meenambigai O 43 2 32.89 3 0.81 2 1 108 215 287 325 80 145 65 2 2 2 2 2 1 150 90 
13. Vasuderan O 40 1 30.79 3 1 2 1 192 341 216 186 42 37 137 2 1 2 2 2 1 150 100 
14. Shahul Hameed O 38 1 32.04 3 0.98 2 1 235 375 206 193 45 143 38 2 2 2 2 2 1 140 90 
15. Jayanthi O 47 2 30.33 3 0.95 2 2 106 300 260 96 48 193 19 2 2 1 2 1 1 150 86 
16. Nazira L 52 2 18.49 1 0.91 2 2 312 418 226 146 47 150 29 1 2 1 1 2 2 120 80 
17. Thangavel O 50 1 30.47 3 0.96 2 1 128 298 187 89 51 119 17 2 1 2 1 2 2 110 84 
18. Chandra N 45 2 23.63 2 0.93 2 2 132 246 186 118 47 116 23 2 2 1 2 2 2 110 70 
19. Selvi  O 38 2 30.32 3 0.9 2 1 271 446 222 86 56 149 17 2 1 1 2 2 2 100 70 
20. Muthukutti L 55 1 18.36 1 0.91 1 2 366 490 201 186 66 114 21 2 1 2 1 2 2 100 74 
21. Murugaiyan O 62 2 30.45 3 0.97 2 2 133 270 244 102 56 168 20 2 2 1 2 2 1 140 100 
22. Chinnaponnu N 60 2 21.09 2 0.85 2 2 212 360 124 198 47 35 39 2 1 2 2 2 1 140 100 
23. Chellammal N 52 2 22.01 2 0.88 2 2 139 232 209 115 61 144 116 2 1 2 2 2 2 120 80 
24. Amutha N 45 2 21.17 2 0.94 2 2 246 486 250 162 74 144 116 2 2 1 2 2 2 120 70 
25. Babulal  N 60 1 21.3 2 0.93 1 1 250 452 178 348 44 65 69 1 2 2 2 2 1 170 96 
26. Gnanasekaran L 65 1 18.08 1 0.88 1 1 318 499 203 109 35 126 22 1 2 1 2 1 2 120 80 
27. Selvaraj N 48 1 19.53 2 0.97 2 1 210 337 276 155 80 165 31 2 2 2 1 2 2 110 80 
28. Kamarchi N 58 2 20.5 2 0.83 2 2 233 388 164 145 89 29 96 2 1 2 2 2 2 120 76 
29. Chinnasamy N 64 1 21.09 2 0.89 1 2 160 324 167 55 39 117 11 2 1 2 2 2 2 120 70 
30. Subbulakshmi O 56 2 37.02 3 1 2 1 210 498 185 255 42 51 92 1 2 2 2 2 1 160 100 
31. Shyamala N 58 2 22.5 2 0.98 2 2 188 346 250 172 40 186 34 2 2 2 1 2 2 120 80 
32. Rubella mary N 64 2 19.13 2 0.89 2 2 140 299 220 141 38 154 28 2 2 2 2 2 1 150 90 
33. Sarfunnissa O 53 2 30.47 3 0.92 2 1 309 430 246 81 38 198 16 2 2 2 1 2 1 140 96 
34. Angayee N 58 2 21.77 2 0.89 2 1 176 298 192 138 36 125 27 1 2 2 2 2 1 150 90 
35. Jovan  O 58 1 33.91 3 0.92 2 1 185 399 223 123 45 153 24 1 2 2 2 2 1 150 96 
36. Chockalingam O 55 1 30.45 3 0.97 2 2 129 230 202 68 64 125 13 2 2 2 2 2 1 150 100 
37. Rajalingam O 58 1 35.15 3 0.91 1 1 134 286 159 42 64 42 13 2 1 2 2 2 1 160 100 
38. Chinnammal N 54 2 23.78 2 0.82 2 2 180 366 252 81 38 198 16 2 2 2 2 2 1 120 80 
39. Rangasamy L 60 1 18.49 1 0.81 1 2 356 444 168 60 48 108 12 2 1 2 2 2 2 110 74 
40. Annabakiyam N 64 2 19.59 2 0.9 2 2 169 350 223 58 40 172 11 1 2 2 2 2 2 120 80 
41. Gnanaprakasam L 60 1 18.22 1 0.85 1 2 204 386 194 96 68 107 19 2 1 2 2 2 2 120 70 
42. Pappa  L 58 2 17.36 1 0.86 2 2 210 348 198 104 58 118 22 2 2 2 1 2 2 110 70 
43. Saroja N 60 2 23.31 2 0.81 2 2 145 304 262 148 51 183 29 2 2 2 1 2 1 140 94 
44. Kalaivani L 48 2 18.17 1 0.85 2 1 176 281 173 98 46 108 19 2 2 1 2 2 2 110 70 
45. Abdual kadhar O 57 1 22.49 3 0.93 1 1 280 364 225 162 38 155 32 1 2 2 2 2 1 160 96 
46. Mohammed Ali N 62 1 24.03 1 0.92 1 1 160 327 246 148 45 172 29 1 2 2 2 2 1 134 98 
47. Gandhimathi L 58 2 17.31 1 0.84 2 2 208 430 138 98 35 82 19 2 2 1 2 2 2 110 70 
48. Sabeera N 60 2 23.78 2 0.81 2 2 204 378 152 208 25 86 41 2 1 2 2 2 2 120 80 
49. Parvathi O 55 2 30.12 3 0.92 2 2 190 470 188 105 29 140 21 1 1 2 2 2 1 150 100 
50. Senthamilselvan N 38 1 24.8 2 0.97 2 2 392 403 182 146 28 125 29 2 2 2 2 1 1 160 100 
51. Raman O 62 1 31.2 3 0.97 2 2 192 332 202 97 43 140 19 1 2 2 2 2 2 120 80 
52. Govindharajan N 65 1 19.48 2 0.86 1 2 176 223 184 97 28 137 19 2 1 1 2 2 2 120 80 
53. Deepa N 34 2 20.81 2 0.85 2 1 198 306 174 95 30 125 19 2 2 2 2 1 2 110 84 
54. Aminabeevi N 56 2 20.44 2 0.83 2 2 190 384 170 97 29 128 19 2 1 2 2 1 2 100 70 
55. Fathima O 56 2 36.44 3 0.92 2 1 192 340 175 95 44 112 19 1 1 1 2 2 1 160 100 
56. Maruthai L 54 1 18.49 1 0.88 1 2 196 364 161 165 48 84 29 2 2 1 1 2 2 110 60 
57. Adiakalaraj N 60 1 23.81 2 0.95 1 2 160 386 225 106 32 171 22 1 2 2 2 2 1 150 100 
58. Rengasamy N 50 1 19.83 2 0.93 1 2 280 392 201 145 42 132 29 1 2 1 2 1 2 100 70 
59. Saradha N 52 2 22.19 2 0.91 2 2 184 402 256 178 43 178 45 1 2 2 2 2 1 130 96 
60. Kulanthaisamy O 64 2 33.78 3 0.97 2 2 108 288 286 164 38 216 32 1 2 2 2 2 2 120 80 
61. Abdulla Sheriff O 62 1 30.22 3 0.93 1 2 134 268 280 162 43 208 32 1 2 1 2 2 2 110 78 
62. Haneef Beevi N 63 2 22.35 2 0.88 2 1 206 392 200 162 52 118 32 2 2 2 1 2 2 100 70 
63. Chellammal L 55 2 18.37 1 0.78 2 2 284 262 167 184 68 62 37 2 2 1 2 1 2 120 70 
64. Mari susairaj O 54 2 30.13 3 0.89 2 2 114 338 266 188 42 186 38 1 2 2 2 2 1 150 90 
65. Rasayee N 60 2 20.27 2 0.9 2 2 182 449 165 152 54 85 30 2 1 2 2 2 2 100 60 
66. Mookammal N 65 2 20.54 2 0.91 2 1 176 281 184 142 68 88 28 2 2 1 1 2 2 90 60 
67. Shaitha  N 52 2 20.49 2 0.89 2 1 212 438 184 82 34 134 16 1 2 2 2 2 1 160 94 
68. Bommakka N 58 2 24.92 2 0.96 2 2 138 207 184 99 45 119 20 2 2 2 2 2 1 150 100 
69. Geetha L 57 2 18.31 1 0.79 2 2 196 292 153 173 36 93 24 2 2 2 1 2 2 110 80 
70. Paulraj O 65 1 33.33 3 1 2 2 179 232 226 168 42 155 29 2 2 1 2 1 2 100 60 
71. Anjammal O 60 2 30.04 3 0.88 2 2 308 410 230 172 42 156 32 2 2 1 2 2 1 140 94 
72. Kannaiyan L 64 1 18.43 1 0.88 1 2 310 415 166 114 68 75 23 2 2 1 2 1 2 100 60 
73. Balakrishnan N 65 1 22.15 2 0.92 1 2 280 394 204 158 41 133 32 1 2 2 2 2 2 120 84 
74. Noorjehan N 59 2 22.03 2 0.79 2 2 238 400 198 166 42 123 33 2 2 1 2 2 2 100 70 
75. Chinnan O 58 1 30.42 3 0.93 1 2 156 340 188 177 42 113 33 1 2 1 2 2 2 120 80 
76. Khairunnissa L 58 2 18.26 1 0.79 1 2 258 324 168 172 44 90 34 2 2 1 2 1 2 120 64 
77. Mohan N 55 1 20.95 2 0.86 1 2 168 336 220 168 40 156 34 1 1 2 2 2 1 160 110 
78. Madhavan O 59 1 31.89 3 0.97 2 2 210 450 282 178 30 217 35 1 2 2 2 2 1 140 100 
79. Nallammal L 45 2 16.82 1 0.85 2 2 270 396 166 200 64 62 40 2 2 1 1 2 2 100 70 
80. Ganesan O 64 1 30.1 3 0.97 2 2 180 306 174 124 30 122 32 1 2 2 2 2 1 150 90 
81. Mangalam L 65 2 17.78 1 0.79 1 2 250 486 148 164 56 68 24 2 2 2 2 1 2 100 68 
82. Palanisamy N 58 1 21.25 2 0.88 1 1 156 395 167 242 45 100 22 1 2 2 2 2 2 110 84 
83. Saravanan N 63 1 22.14 2 0.9 1 1 180 326 200 176 45 120 35 2 2 2 2 1 2 120 80 
84. Jamesha O 62 2 30.44 3 0.89 2 1 178 388 288 196 35 214 39 1 2 2 2 2 1 170 100 
85. Saminathan N 58 1 20.32 2 0.92 1 2 104 390 186 172 43 111 32 2 2 2 1 2 2 110 70 
86. Raja N 56 1 19.14 2 0.91 1 2 240 401 176 101 34 102 20 2 1 2 2 2 1 148 90 
87. Arumugam N 65 1 22.19 2 0.89 1 2 150 413 202 155 42 127 33 1 2 2 2 2 2 110 80 
88. Sundharamoorthi N 38 1 25 2 0.9 1 1 126 224 172 180 42 104 36 1 2 2 2 2 1 140 90 
89. Murugesan N 45 1 30.47 3 0.97 2 2 136 240 182 166 38 111 33 2 1 2 2 2 1 150 100 
90. Petchiammal O 62 2 30.79 3 0.93 2 2 188 256 282 188 28 117 37 1 2 2 2 2 2 110 70 
91. Shajehan O 39 1 33.05 3 0.95 2 1 165 310 236 170 32 170 34 2 2 2 2 2 1 160 90 
92. Mahmoodha O 68 2 35.49 3 1 2 1 192 400 198 166 42 91 33 2 2 1 1 2 2 120 80 
93. Mariyasusai O 65 1 30.47 3 0.95 2 2 174 388 204 164 32 137 35 2 2 2 2 1 2 100 70 
94. Kuppammal N 60 2 22.1 2 0.79 2 2 186 362 204 137 44 136 24 1 2 2 2 2 1 140 90 
95. Susheela N 55 2 23.44 2 0.79 1 2 92 260 216 156 45 140 31 2 2 1 1 2 2 100 60 
96. Abidha N 41 2 22.14 2 0.79 2 2 262 436 188 160 40 116 32 2 1 2 2 2 2 110 60 
97. Padma N 62 1 21.78 2 0.91 1 2 196 278 168 140 42 90 28 1 2 2 2 2 1 140 90 
98. Neelambal N 40 2 23.81 2 0.79 1 1 128 391 184 166 42 109 33 2 2 2 1 2 2 120 80 
99. Manikandan N 65 1 20.44 2 0.79 1 2 192 400 188 110 32 134 22 2 1 2 2 2 2 120 70 
100. Gopalan N 62 1 23.12 2 0.79 1 2 204 382 180 117 34 125 21 1 2 2 2 2 2 120 70 
 
Sex:    1-Male  
   2-Female 
BMI:   L-Lean(1) 
   N-Normal weight (2) 
   O-Obese (3) 
Family History: 1-Yes 
   2-No  
Complication: 1-Yes 
   2-No 
 
ABBREVIATIONS 
 
BMI   - Body Mass Index 
WHR  - Waist Hip Ratio 
DM   - Diabetes Mellitus 
MODY - Maturity onset diabetes of the young 
CHO  - Carbohydrate  
LADA - Latent Auto immune diabetes in aduls 
IGT  - Impaired glucose tolerance 
TC  - Total Cholesterol  
TGL  - Triglycerides  
HDL  - High Density Lipoproteins 
LDL  - Low Density Lipoprotein 
VLDL  - Very Low Density Lipoprotein 
FPG  - Fasting Plasma Glucose 
PPG  - Postprandial Plasma Glucose 
AGE  - Advance Glycosylation end product 
ADA  - American Diabetes Association  
NGSP  - National Glycohemoglobin Standardization programme.   
DCCT  - Diabetes Complication Control Trial  
 
